Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma

Maintaining relative dose intensity (RDI) of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Pegfilgrastim was approved in Japan in November 2014 to prevent febrile neutropenia (FN) and main...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Yuka, Kanemasa, Yusuke, Sasaki, Yuki, Ohigashi, An, Tamura, Taichi, Nakamura, Shohei, Yagi, Yu, Kageyama, Akihiko, Omuro, Yasushi, Shimoyama, Tatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913099/
https://www.ncbi.nlm.nih.gov/pubmed/35451406
http://dx.doi.org/10.1097/MD.0000000000029028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913099/
https://www.ncbi.nlm.nih.gov/pubmed/35451406
http://dx.doi.org/10.1097/MD.0000000000029028

Ejemplares similares